The phenomenon of endotoxin tolerance has been widely investigated, but to date, the molecular mechanisms of endotoxin tolerance remain to be resolved clearly. The discovery of the Toll-like receptor (TLR) family as the major receptors for lipopolysaccharide (LPS) and other bacterial products has prompted a resurgence of interest in endotoxin tolerance mechanisms. Changes of cell surface molecules, signaling proteins, pro-inflammatory and anti-inflammatory cytokines and other mediators have been examined. During tolerance expression of LPS-binding protein (LBP), CD14, myeloid differentiation protein-2 (MD-2) and TLR2 are unchanged or up-regulated, whereas TLR4 is transiently suppressed or unchanged. Proximal post-receptor signaling proteins that are altered in tolerance include augmented degradation of interleukin-1 receptor-associated kinase (IRAK), and decreased TLR4-myeloid differentiation factor 88 (MyD88) and IRAK-MyD88 association. Tolerance has also been shown to be associated with decreased G i protein content and activity, decreased protein kinase C (PKC) activity, reduction in mitogen-activated protein kinase (MAP kinase) activity, and reduced activator protein-1 (AP-1) and nuclear factor kappa B (NF-kB) induced gene transactivation. However, not all signaling proteins and pathways are suppressed in tolerance and induction of specific anti-inflammatory proteins and signaling pathways may serve important counter inflammatory functions. The latter include induction of IRAK-M and suppressor of cytokine-signaling-1 (SOCS-1), phosphoinositide-3-kinase (PI3K) signaling, and increased or maintained expression of inhibitor-kB (IkB) isoforms. Also at the nuclear level, increase in the NFkB subunit p50 homodimer expression and increased activation of peroxisome-proliferatoractivated receptors-g (PPARg) have been linked to tolerance phenotype. Although there are species and cellular variations in manifestation of the LPS tolerant phenotype, it is clear that the tolerance phenomena have evolved as a complex orchestrated counter regulatory response to inflammation.
INTRODUCTION
Bacterial LPS, a membrane glycolipid of Gram-negative bacteria, is a potent inducer of pro-inflammatory responses in monocytes, macrophages, and neutrophils, which has been linked to fatal sepsis syndrome. 1 An interesting property of bacterial LPS is endotoxin tolerance. Endotoxin tolerance is defined as a reduced capacity of the host (in vivo) or of cultured macrophage/monocyte (in vitro) to respond to LPS activation following a first exposure to this stimulus. Although endotoxin tolerance was first studied by Beeson 50 years ago, 2 to date the molecular mechanisms of endotoxin tolerance remain to be clearly resolved. Since the discovery of the TLR family as the major receptors for LPS and other bacterial products, many investigators have focused on changes in the TLR signaling pathways as a mechanism of endotoxin tolerance. Changes of cell surface molecules, signaling proteins, pro-inflammatory and anti-inflammatory cytokine and other mediator gene expression have been examined. LPS tolerance has also been termed hyporesponsiveness, refractoriness, adaptation, de-activation, desensitization, immunoparalysis or reprogramming. 3, 4 However, LPS tolerance is not a global down regulation of signaling protein and mediator production. The LPS tolerant animal and cells can still respond to further LPS challenge and express specific genes and proteins. 5 Therefore, the terms adaptation and reprogramming may be better synonyms for tolerance.
This review will focus on the molecular mechanism of LPS tolerance. Other aspects of LPS tolerance such as broad historical perspective, in vivo studies, cross tolerance, and clinical implications have been recently reviewed by Cross, 6 West and Heagy, 4 Dobrovolskaia and Vogel, 7 and Cavaillon et al.
8

LPS SIGNALING
LPS induces cellular responses by complexing with circulating LBP and subsequently binding to CD14, a glycosylphosphatidylinositol (GPI)-anchored cell surface protein, with high affinity for LPS. 9 However, CD14 lacks an intracellular domain, and LPS signal transduction has been shown to be mediated by other receptors. Receptor complexes including complement receptor type III, 10, 11 heat shock proteins, chemokine receptor CXCR4, growth differentiation factor 5, 12 and caspase activator Nod-1 13 have all been implicated in the initial steps of LPS recognition and signaling. Since the discovery of the TLR family, most studies have implicated a role of the TLRs in LPS signaling. 14 TLR family members are transmembrane proteins with an extracellular domain containing leucine-rich repeats and a cytoplasmic domain homologous to that of the interleukin (IL)-1 receptors. 15 It is now clear that TLR4 is the major receptor for LPS signaling, whereas TLR2 is involved in Gram-positive bacteria signaling except for LPS from Leptospira interrogans and Porphyromonas gingivalis which have been shown to signal through TLR2. [16] [17] [18] MD-2, a soluble protein associated with TLR4 at the cell surface, has been found necessary for LPS response. 19 TLRs trigger a common intracellular signaling pathway that involves the adaptor proteins MyD88. Upon activation, IRAK is recruited to the receptor through MyD88, where it is phosphorylated, rapidly degraded and then relays the signal downstream by interacting with TNF receptor activated factor 6 (TRAF6). Another adaptor protein Toll-interacting protein (TOLLIP) negatively regulates IRAK activity and degradation. 20 Downstream of TRAF6, LPS signaling leads to activation of transforming growth factor-b-activated kinase-1 (TAK1) 21 and NF-kB-inducing kinase (NIK). The latter activates the inhibitory kB kinase (IKK) complex leading to the phosphorylation and degradation of IkB protein and release of NF-kB. 22 The TAK1 complex has also been reported to activate MAP kinase. 23 Evolutionary conserved signaling intermediate in Toll pathway (ECSIT) is another molecule that bridges TRAF6 to MAP kinase and NF-kB. 24 Finally, NF-kB and AP-1 are activated, which leads to pro-, anti-inflammatory cytokine and other mediator gene expression. Besides the core pathway for LPS signaling, other signaling molecule such as Toll/IL-1 receptor domain-containing adaptor protein (TIRAP) or MyD88-adaptor-like (MAL), 25, 26 which mediate MyD88-independent signaling pathway, heterotrimeric G i proteins, 27 PKC, 28 and PI3K 29 also have been implicated in regulating LPS signaling (Fig. 1) . These signaling pathways have been reviewed by Dobrovolskaia and Vogel. 7 This review focuses on changes in cell-surface binding molecules, postreceptor signaling proteins, cytoplasmic proteins, and nuclear transcription events as potential molecular mechanisms of LPS tolerance.
Binding proteins and cell surface molecule alterations in endotoxin tolerance
When LPS is released from the Gram-negative bacterial cell wall, it binds with LBP, present in serum. LPS tolerance can be induced in THP-1 cells maintained in serumfree medium suggesting that LBP is not necessary for tolerance induction. 30 Jarvelainen et al. 31 using the RT-PCR technique demonstrated that after chronic LPS treatment, the LBP mRNA from liver of rats was not significantly changed. However, high levels of LBP and high levels of soluble CD14 were found in the serum from septic patients. 32, 33 It has been speculated that high levels of these molecules may neutralize LPS and inhibit LPS-induced activation. 33 A potential mechanism for tolerance to LPS is downregulation of the receptor molecules. There have been many studies of cell surface molecular changes in LPS tolerance (Table 1) . CD14 was identified as the primary receptor of LPS, which binds LPS with high affinity. 34, 35 GPI-anchored CD14 and soluble CD14 facilitates the interaction between LPS and TLR4. 36 Labeta et al. 37 analyzed the CD14 expression in tolerance to LPS in the human monocytic cell line Mono-Mac-6. Instead of down-regulation, CD14 cell-surface expression was up-regulated in the cells treated with LPS for 48 h. Similar studies performed by Ziegler-Heitbrock et al. 38 demonstrated that CD14 mRNA and CD14 cell-surface expression was up-regulated in Mono-Mac-6 rendered tolerant by Salmonella minnesota LPS (SmLPS). However, other investigators have found no change in CD14 expression after LPS tolerance induction. Mathison et al. 39 found that CD14 cell-surface expression was unchanged by exposure of rabbit peritoneal exudates macrophages with SmLPS. McCall et al. 40 compared human blood neutrophil CD14 cell-surface expression between healthy volunteers and patients with sepsis syndrome and found no significant difference. It has also been observed that CD14 expression on the surface of murine macrophage cell line P388D1 was unchanged following LPS tolerance induction. 41 CD14 mRNA expression was unchanged in liver of chronic LPS treated rats. 31 In peritoneal macrophages from C57BL/6J mice, CD14 cell-surface expression was unchanged by pretreatment with purified SmLPS or Escherichia coli LPS (EcLPS). 42 Martin et al. 43 compared protein-free EcLPS and LPS from Porphyromonas gingivalis (PgLPS). They found that in the human monocytic cell line THP-1 cells, CD14 cell-surface expression was up-regulated by pretreatment with PgLPS. The latter LPS has been shown to signal through TLR2. However, CD14 cell-surface expression was unchanged by pretreatment with EcLPS, which signals through TLR4. Taken together, CD14 cell-surface expression is either unchanged by LPS signaling through TLR4, or up-regulated by LPS strains that signal through TLR2. Therefore, suppression of CD14 expression cannot be a mechanism of LPS tolerance. Also LPS tolerance has recently been shown to be induced in anti-CD14 antibody treated THP-1 cells and human monocytes further suggesting that CD14 is not involved in induction of LPS tolerance. 30 LPS-mediated signaling through TLR4 requires MD-2, which physically associates with TLR4. 19 It was reported that in peritoneal macrophages from C57BL/6J mice, MD-2 mRNA expression was unchanged by pretreatment with SmLPS. 44 Studies performed by Medvedev et al. 45 demonstrated that human monocyte, MD-2 mRNA expression was slightly up-regulated by EcLPS stimulation. However, Adib-Conquy and Cavaillon 46 demonstrated that Molecular mechanisms of endotoxin tolerance 73 In LPS tolerance, expression of LBP and CD14 are unchanged or up-regulated, whereas TLR4 is transiently suppressed or unchanged. Augmented degradation of IRAK, decreased G i protein content, decreased PKC activity, may reduce downstream signaling to MAP kinase and NF-kB. In contrast to decreased signaling proteins, IRAK-M and SOCS-1 expression are increased. Also, in LPS tolerance, the PI3K pathway is maintained, and increased or maintained expression of IkB isoforms occurs. The latter signaling proteins and pathways may be important counter-inflammatory mechanisms. Finally, at the nuclear level, there is decreased AP-1 and NF-kB transactivation but an increase in the p50 homodimer expression and activation of PPARg, which suppress transcription of pro-inflammatory genes.
in peripheral blood mononuclear cells (PBMC), MD-2 mRNA expression was down-regulated by pretreatment with EcLPS. Thus, to date, data are inconsistent with regard to changes of MD-2 mRNA expression upon LPS pretreatment. It has been demonstrated that genetically LPS-hyporesponsive C3H/HeJ mice have a mutation in the Tlr4 gene.
14 Since TLR4 appears to be the main Toll-like receptor for LPS, down-regulation of TLR4 cell-surface expression has been examined as a possible mechanism of LPS tolerance (Table 1 ). In a study by Poltorak et al., 14 TLR4 mRNA expression was transiently reduced by 2-h LPS stimulation in macrophage cell line RAW 264.7. Consistent with this concept, Nomura et al. 42 reported that in RAW264.7 cells and peritoneal macrophages from C57BL/6J mice, TLR4 mRNA expression was markedly decreased by treatment with EcLPS for intervals up to 12 h. The TLR4 mRNA returned to normal levels at 24-h LPS treatment. Nomura et al. 42 also found that in the peritoneal macrophages from C57BL/6J mice, TLR4-MD2 cell-surface expression was reduced by 24-h treatment with EcLPS. Interestingly, they showed that down-regulation of TLR4 cell-expression was also found in C3H/HeJ mice, which have a mutation of the TLR4 gene. These data suggest that down-regulation of TLR4 cell-expression occurs independently of a TLR4-dependent signaling pathway. It was also demonstrated that in THP-1 cells, TLR4 cell-surface expression was decreased by EcLPS pretreatment. 43 In macrophages of C3H/OuJ mouse and human monocytes, TLR4 mRNA was decreased by EcLPS treatment. 45, 47 However, in studies performed by Adib-Conquy and Cavaillon 46 in human PBMC, TLR4 mRNA expression was reduced by pretreatment with EcLPS, while the TLR4 cellsurface expression was not significantly changed. Other studies in human monocytes and Chinese hamster ovary (CHO)-CD14 cells (CHO cells stably transfected with the 74 Fan, Cook human CD14 cDNA) demonstrated that TLR4 cell-surface expression was unchanged upon LPS stimulation. 48 It was also reported that in macrophages from BALB/c mice and RAW 264.7 cell line, TLR4 mRNA expression was unchanged upon LPS treatment. 49 Besides these findings showing TLR4 mRNA and protein expression were decreased or unchanged upon LPS stimulation, there are also studies showing that TLR4 mRNA expression was increased by LPS stimulation. Studies with rat cardiac myocytes and coronary microvascular endothelial cells, 50 human PBMC and polymorphonuclear cells (PMNs), 51 human dermal microvessel endothelial cells (HMECs), 52 show TLR4 mRNA up-regulation by LPS stimulation. Yeo et al. 53 reported that in RAW 264.7 cells, TLR4 mRNA expression was initially decreased within 8 h then returned to normal level upon SmLPS treatment, while expression of surface TLR4-MD2 was decreased within 8 h after LPS stimulation, but increased at later time periods. Since LPS tolerance can persists for several days, 6 the mechanism of LPS tolerance seems unlikely to be attributed solely to decrease TLR4-MD2 cell-surface expression. Furthermore, Medvedev et al. 48, 54 overexpressed CD14, TLR4, and MD-2 in human embryonic kidney (HEK) 293T cells and CHO-CD14 cells. Despite the TLR4 overexpression, LPS tolerance still induced decreased NF-kB activation and MAP kinase activation when re-challenged with LPS. Thus induction of LPS-tolerance in this system appears to occur with signaling proteins downstream of TLR4.
In addition to TLR4, TLR2 cell-surface expression in LPS tolerance has been investigated ( Table 1) . It was reported that in human PBMC, TLR2 mRNA expression was unchanged by EcLPS pretreatment, but in human PMN, TLR2 mRNA expression was increased by EcLPS stimulation. 51 In THP-1 cells, TLR2 cell-surface expression was increased by pretreatment with PgLPS, a TLR2 agonist, but unchanged by pretreatment with EcLPS, a TLR4 agonist. 43 In peritoneal macrophages from C57BL/6J mice, TLR2 mRNA expression was unchanged by SmLPS pretreatment. 44 Studies with peritoneal macrophages from BALB/c mice, 49 C3H/OuJ mice, 47 and RAW264.7 cells 49 have shown that TLR2 mRNA expression was up-regulated by LPS pretreatment. Faure et al. 52 found that in HMECs, TLR2 mRNA expression, TLR2 protein expression and TLR2 cell-surface expression were all increased by EcLPS stimulation. These findings were confirmed in human monocytes. 45 Thus most investigators have found that TLR2 expression is up-regulated when LPS tolerance was induced. The mechanism of TLR2 up-regulation is currently unknown, but it has been shown that blocking NFkB activation abrogates the induction of TLR2 mRNA. 49, 52 Analysis of the 5¢ upstream promoter region of the murine tlr2 gene demonstrates the existence of two NF-kB binding sites that are important in the ability of LPS to induce tlr2 gene expression. 55, 56 Based upon a number of studies in LPS tolerant cells, cell surface molecules LBP and CD14 are unchanged or up-regulated, TLR4-MD2 is transiently decreased or unchanged, while TLR2 is up-regulated. Therefore, the mechanism of LPS tolerance cannot be simply explained as down-regulation of cell surface receptors.
Proximal post-receptor signaling protein alterations in endotoxin tolerance
Upon cell surface receptor activation, IRAK is recruited to the receptor through adaptor protein MyD88, which then relays signaling downstream to TRAF6. It has been observed in the peritoneal macrophages from C57BL/6J mice 44 and C3H/OuJ mice, 47 murine macrophages RAW264.7 cells, 53 human promonocytic THP-1 cells 57 and human monocytes 45 that mRNA and protein expression of MyD88 and TRAF6 are unchanged upon LPS stimulation. However, Medvedev et al. 45 found that pretreatment of human monocytes with LPS decreased TLR4-MyD88 association induced by LPS re-stimulation. The mechanism by which LPS tolerance induction affects TLR4-MyD88 association remains unknown. Subsequently, Adib-Conquy and Cavaillon 46 showed that in LPS-tolerant human PBMC, IRAK-MyD88 association was decreased upon LPS re-stimulation. Interferon-g (IFN-g) and granulocyte macrophage colony-stimulating factor (GM-CSF) reversal of tolerance was associated with increased IRAK content and IRAK-MyD88 association. It was also found that in LPS-tolerant THP-1 cells, IRAK-MyD88 association was decreased, but IRAK-TRAF6 association was unchanged. 57 It is possible reduction of IRAK-MyD88 association may be indirectly affected by decreased TLR4-MyD88 association.
Another adaptor protein besides MyD88 is TIRAP/ MAL. 25, 26 LPS induced inflammatory cytokine production is inhibited in mice lacking TIRAP. 58, 59 As in MyD88-deficient mice, LPS activation of NF-kB and MAP kinase is induced with delayed kinetics in TIRAP deficient mice. 58 Therefore, TIRAP appears to play a crucial role in the MyD88-dependent signaling pathway shared by TLR2 and TLR4. 58 However, TIRAP mRNA expression was increased in RAW264.7 cells rendered LPS tolerant. 53 TOLLIP is also an adaptor protein downstream of TLRs. 20 It negatively regulates LPS signaling by suppression of phosphorylation and kinase activity of IRAK and impairment of LPS induced NF-kB and AP-1 activation. 20 TOLLIP, therefore, could be another candidate for tolerance-inducing protein. However, in RAW264.7 cells, TOLLIP mRNA was found unchanged upon LPS stimulation. 53 Besides the TLR4-MyD88-IRAK-TRAF6 core signaling pathway, other signaling molecules are also involved in LPS signal transduction. Pretreatment of CHO-CD14 with pertussis toxin (PTx), an inhibitor of G i protein, inhibits LPSinduced extracellular signal-regulated kinase (ERK1/2) and p38 activity, but did not inhibit IkB-a degradation. 27 On the other hand, pretreatment of CHO-CD14 with mastoparan-7, a G i protein agonist, increased LPSinduced MAP kinase activity. 27 Similar results were found in THP-1 cells, pretreatment of THP-1 cells with PTxinhibited c-Jun-NH 2 -terminal kinase (JNK) and p38 phosphorylation, but did not inhibit IkB-a degradation and NF-kB activation. 60 These data suggest that heterotrimeric G i proteins are partly involved in LPS signaling. Our previous studies demonstrated that in peritoneal macrophages from LPS-tolerant rat, GTPase activity, GTP g S binding, and protein content of G i3a and G i2a were significantly decreased. [61] [62] [63] In the same model, it was found that G i3a mRNA expression was also decreased. 64 Thus decreases of G i protein content and function in LPS-tolerant rat may be another manifestation of LPS tolerance.
Guha and Mackman 19 presented evidence that the PI3K pathway negatively regulates LPS signaling. Inhibition of PI3K-Akt pathway in THP-1 cells by wortmannin and LY294002, specific inhibitors of PI3K, and dominant-negative Akt plasmid enhances LPS-induced activation of MAP kinase including ERK1/2, p38 and JNK and downstream targets AP-1 and Egr-1. Inhibition of the PI3K-Akt pathway also enhances LPS-induced NF-kB activation and tumor necrosis factor-a (TNF-a) production. Monick et al. 65 demonstrated that PI3K negatively regulated LPS-induced cyclooxygenase 2 (Cox-2) protein, mRNA expression and release of prostaglandin E 2 (PGE 2 ) through inhibition of p38 activation. Bowling et al. 66 reported that in the peritoneal macrophages from LPS-tolerant rat, PI3K protein expression was increased. In subsequent studies, pretreatment of RAW264.7 cells with wortmannin, a PI3K inhibitor, reversed LPS tolerance by increasing TNF-a production and decreasing nitric oxide (NO) production. 67 It has also been observed that in LPS-adapted THP-1 cells, re-stimulation with LPS still can induce PI3 kinase-dependent signaling pathway leading to phosphorylation of Akt and increased translation efficiency of the anti-inflammatory cytokine secretory IL-1 receptor antagonist (sIL-1 RA). 5 These data suggest that the PI3K pathway remains open in LPS tolerance and negatively regulates LPS signaling to pro-inflammatory mediator and maintaining anti-inflammatory cytokine production.
IRAK alterations in endotoxin tolerance
IRAK plays a crucial role in LPS signaling downstream of TLRs. It is recruited to the receptor upon LPS stimulation, becomes highly phosphorylated, rapidly degraded and relays signaling downstream to TRAF6. 68 Currently, four members of IRAK family (IRAK [IRAK-1], IRAK-2, IRAK-M, and IRAK-4) have been discovered. 69 IRAK and IRAK-4 have kinase activity and mediate LPS signaling. Mice with deletions of IRAK-4 are phenotypically similar to mice lacking adaptor protein MyD88. 69 Animals with a deletion of IRAK-1 are partly resistant to LPS shock. 70 IRAK-4 physically interacts with other IRAKs and presumably signals upstream of the other IRAKs. IRAK-2 is not degraded after TLR4 stimulation, and may be linked to a MyD88-independent pathway. 71 IRAK-M, which is an inactive kinase, negatively regulates LPS signaling. 72 Changes in IRAK function in LPS tolerance have been the focus of recent investigations ( Table 2) .
Pretreatment of peritoneal macrophages from C57BL/6J mice with EcLPS decreased IRAK-1 kinase activity induced by LPS re-stimulation. 42 These findings were confirmed in human monocytes. 45 Li et al. 57 demonstrated that both LPS-induced IRAK kinase activity and IRAK protein content were decreased by pretreatment of THP-1 cells with EcLPS. It has also been found that ethanol-induced tolerance to LPS can be explained by down-regulation of IRAK protein expression and IRAK 76 Fan, Cook 
Cytoplasmic signaling molecule alterations in endotoxin tolerance
Studies performed by West et al. 28 demonstrated that activation of PKC was compromised in the thioglycollate-elicited peritoneal exudate cells obtained from LPStolerant BALBc mice. Treatment of LPS-tolerant macrophage with H7 or staurosporine, inhibitors of PKC, inhibits TNF-a production induced by LPS restimulation. On the other hand, treatment of LPS-tolerant macrophage with phorbol myristate acetate (PMA), which activates PKC, reversed LPS tolerance as shown by an increase TNF-a production. Consistent with these findings, it was found that indolactam V, a more specific activator of PKC exhibited similar effects to PMA, whereas bisindolylmaleimide, a more specific PKC antagonist exhibited similar effects to H7. 76 These data suggest that inhibition of PKC activity also is associated with induction of the tolerant phenotype.
The MAP kinase cascade plays an important role in LPS signaling and contributes to pro-inflammatory and anti-inflammatory cytokine and other mediator gene expression. ERK1/2, JNK and p38 are three major members in this family. They are phosphorylated and activated upon LPS stimulation. 27 Down-regulation of MAP kinase phosphorylation is a significant marker of LPS tolerance. In the peritoneal macrophages from BALBc mice and C3H/HeN mice, pretreatment with LPS inhibited ERK1/2, JNK and p38 phosphorylation upon LPS re-stimulation. 77, 78 Similar results were found in peritoneal macrophages from C57BL/6J mice, 44 C3H/OuJ mice, 47 THP-1 cells, 79 CHO-CD14 cells 48 and human monocytes. 45 Mendez et al. 80 reported that p38 inhibitor CNI-1493 reversed LPS tolerance as evaluated by an increase TNF-a production in peritoneal macrophage from rats. The latter study suggest that activation of p38 MAP kinase is necessary in induction of LPS tolerance. However, in contrast to these data, Kraatz et al. 77 found another p38 inhibitor SB202190 did not block LPS tolerance induction by measuring TNF-a production.
IkB protein is present in the cytoplasm in association with NF-kB. Upon LPS stimulation, IkB is phosphorylated then rapidly degraded. NF-kB translocates to the nucleus and activates transcription of a number of genes that are involved in the inflammatory response. To date, six members of IkB family have been identified: IkB-a, IkB-b, IkB-g, IkB-d, IkB-e and IkB-z. [81] [82] [83] . IkB-g and IkB-d are C-terminal portions of the p105 and p100 precursors of the p50 and p52 subunit of NF-kB. 84, 85 IkB-z, which is the most recently discovered, localizes in the nucleus and binds to p50 subunit of NF-kB to prevent binding of the p50/p65 heterodimer to DNA. 83 Pretreatment of CHO-CD14 cells, peritoneal macrophages from BALBc mice with LPS inhibits IkB-a degradation induced by LPS re-stimulation (Table 3) . 27, 48, 86, 87 In a human ovarian carcinoma cell line, pretreatment with LPS inhibits IkB-a kinase activity and IkB-a degradation induced by LPS stimulation. 88 In rat myocardium, LPS pretreatment inhibited IkB-a degradation induced by secondary LPS stimulation. 89 Medvedev et al. 47 found that LPS induced both IkB-a and IkB-b degradation are inhibited by LPS pretreatment in peritoneal macrophages from C3H/OuJ mice. In THP-1 cells, IkB-a and IkB-b degradation induced by EcLPS was inhibited by EcLPS pretreatment. 43 Pretreatment of mouse peritoneal macrophage with EcLPS or PgLPS significantly inhibited LPS rechallenge induced IkB-e degradation. Also IkB-z mRNA expression was induced by both EcLPS and PgLPS pretreatment. 90 These studies suggest that IkB proteins are not degraded in vitro in LPS-tolerant cells. However, studies by AdibConquy et al. 91 demonstrated that in human PBMC of patients with severe sepsis or major trauma, which become refractory to LPS stimulation, cytoplasmic IkB-a expression was very low. These data thus differ from in vitro studies of LPS tolerance. The similarities and differences between in vitro and in vivo LPS tolerance and the clinical relevance of tolerance has recently been reviewed by Cavaillon et al. 8 It also has been reported that treatment of LPS-tolerant CHO-CD14 cells with the protein synthesis inhibitor cycloheximide resulted in a rapid activation of NF-kB. 86 These data suggest that an inducible, rapidly turning over proteins may contribute to the development of LPS tolerance. IkB proteins are the best candidates. Our previous studies have shown that cycloheximide did not alter IkB-a content in control cells, but rapidly depleted cellular IkB-a in LPS desensitized cells suggesting that there is increased turn-over of IkB-a in tolerance. 27 Increased cytoplasmic IkB-a content in desensitized cells may be a result of an increase in synthesis and/or altered IkB-a degradation by newly synthesized protein.
SOCS-1 is rapidly induced by LPS and negatively regulates LPS signaling. 92 SOCS-1 suppressed LPS induction of NF-kB reporter gene activity by directly associating with IRAK. SOCS-1 deficient mice are more sensitive to LPS challenge and produce more TNF-a and IL-12 upon LPS stimulation compared to wild-type mice. In a separate study, LPS tolerance was reduced in SOCS-1 deficient mice as shown by increased TNF-a and IL-6 production compared to the wild-type mice. 93 These data suggest that SOCS-1 may play an important role in LPS tolerance.
Nuclear factor alterations in endotoxin tolerance
LPS stimulation activates transcription factors NF-kB and AP-1, which leads to pro-and anti-inflammatory cytokine and other mediator gene expression. The NFkB family is composed of various members, p50 (NFkB1), p52 (NF-kB2), p65 (RelA), RelB, and c-Rel, which can form homo-and heterodimers. 94, 95 The p105 and p100 are precursors of p50 and p52, respectively. Numerous studies have shown that the transactivator form of NF-kB is the p65 unit whereas the p50/p50 homodimer has a minimal transactivation capacity. 96 Upon LPS stimulation, p50/p65 heterodimer complex is predominant, which leads to gene transactivation. Suppression of NF-kB activation in LPS-tolerant cells has been observed in RAW264.7 cells, 97 peritoneal macrophages from BALBc mice, 87 C57BL/6J mice, 42, 44 C3H/OuJ mice 47 and C3H/He mice, 98 CHO-CD14 cells, 48 human monocytes 45 and PBMC from healthy donors 46 (Table 3) . Ziegler-Heitbrock et al. 38, 41, 99 observed that in the human monocytic cell line Mono-Mac-6 and murine macrophage P388D1, pretreatment with SmLPS decreased p50/p65 heterodimer and increased p50/p50 homodimer upon LPS re-stimulation. These authors also found that the precursor of p50, p105 mRNA was up-regulated in LPStolerant cells, while p65 mRNA remain unchanged. 38 Also, over-expression of p50 protein in HEK 293 cells blocks p65-driven transactivation of human TNF promoter. The p50/p50 homodimer competes with p50/p65 heterodimer binding to promoter regions blocking activity of p65. 99 These composite data demonstrate that a shift in subunit composition of NF-kB favoring p50 is a mechanism of LPS tolerance. Although changes in p50 are typically found in myeloid cells, other changes have been found in B-cells rendered LPS tolerant. In a weakly CD14 positive RPMI 8226 clone 1 B cell line, p50 was not up-regulated in LPS tolerance, while the expression of p52, which normally is not highly expressed in cytoplasm, was dramatically increased. The expression of p52 precursor, p100 was also increased in LPS tolerance. Over-expression of p52 reduces activation of the TNF promoter gene constructs. 100 Kravchenko et al. 86 reported that in LPS-tolerant CHO-CD14 cells, NF-kB activation was decreased upon LPS re-stimulation. In peritoneal exudate macrophages from p50 -/-mice, LPS tolerance was not observed. 101 These findings further corroborated the importance of p50 in LPS tolerance. In contrast to these findings, Wysocka et al. 102 more recently reported that LPS tolerance still could be induced in splenocytes derived from p50 -/-, p52
, and RelB-deficient mice as measured by the splenocyte production of IL-12 and TNF-a. The reason for the difference between this study and previous studies are unknown. In other studies, it has been found that in the rat alveolar macrophage cell line NR8383, LPS pretreatment impaired activation of NF-kB in response to LPS re-stimulation by depletion of both p65 and p50 subunit of NF-kB in the cytoplasm of cells, leading to a decrease p65 protein content in the nucleus. 103 In PBMC from patients with severe sepsis and major trauma, the expression of cytoplasmic p65, p50 and p50/p65 heterodimer were significantly reduced, and subsequent in vitro stimulation of PBMC from these patients with LPS did not induce further NFkB transactivation. 91 Surviving patients expressed low level of both p65/p50 heterodimer and p50/p50 homodimer, whereas non-surviving patients expressed predominance of inactive p50/p50 homodimer and showed very low p65/p50:p50/p50 ratios. The clinical relevance of these changes in NF-kB subunit composition relative to experimental tolerance remain uncertain.
Another transcription factor AP-1 family consisting of Fos (c-Fos, FosB, Fra-1, and Fra-2) and Jun (c-Jun, JunB, and JunD) is also activated by LPS through MAP kinase. In mouse macrophage-like cell line P388D1, LPS pretreatment decreased JunB mRNA expression upon secondary LPS stimulation. 104 AP-1 DNA binding activity was decreased in LPS-tolerant peritoneal macrophage from C3H/OuJ mice and RAW264.7 cells. 47 PPARs are a family of ligand-activated nuclear transcription factors which upon binding of the ligand, form heterodimers with the receptor for 9-cis-retinoic acid, retinoid X receptor, and subsequently activate or suppress target gene transcription. 105 So far three isotypes for these receptors have been identified -a, b/d, and g. PPAR-g negatively regulates macrophage activation by decreasing TNF-a, IL-6, IL-1b and NO production. 106, 107 In Kupffer cells, PPAR-g agonists inhibit NO and TNF-a production induced by LPS. 108 Von Knethen et al. 109 demonstrated that LPS tolerance results in activation of PPAR-g using gel shift assay. A PPAR-g reporter construct containing a triple PPAR-responsive element (PPRE) in front of a thymidine kinase minimal promoter driving the luciferase gene was also used. Pretreatment of RAW 264.7 cells with LPS/IFN-g leads to activation of PPAR-g driving luciferase activity. Decoy oligonucleotides, which was used to block the natural PPRE, blocked LPS-induced tolerance. The PPAR-g agonist 15-deoxy-D 12, 14 -prostaglandin J 2 , BRL 49653, and ciglitazone reproduce the effects of LPS tolerance. These data suggest PPAR-g may play a role in LPS tolerance at the transcriptional level.
LaRue et al. 110 demonstrated that inhibition of protein synthesis by cycloheximide reverses the tolerance phenotype of suppressed IL-1b transcription. These data suggest protein synthesis is important in maintenance of state of tolerance. Synthesis of phosphatases may be a factor that functions as a suppressor of transcription in tolerance. Yoza et al. 111 reported that pretreatment of THP-1 cells with okadaic acid, the inhibitor of serine/threonine phosphatases, reversed the toleranceinduced expression of IL-1 and stabilized IL-1b mRNA. Our studies also have shown that okadaic acid augments Cox-2 and TNF-a mRNA expression in the LPS-tolerant cells. 112 These findings suggest that activation of serine/threonine phosphatases may be another potential mechanism of LPS tolerance.
Autocrine mediators of endotoxin tolerance
Mediators induced by LPS can affect the inflammatory phenotype by autocrine feed-back pathway. The most well-studied pro-inflammatory cytokine in LPS signaling is TNF-a. Both in vivo and in vitro studies show that pre-exposure animals or cell lines with low-dose LPS produce significant decreases TNF-a in response to subsequent LPS stimulation. This phenomenon has been observed in many myeloid lineage cells such as murine macrophage, human monocyte and human PBMC. 4 In LPS-tolerant rats, soluble TNF receptor I expression is increased by LPS stimulation. 113 Also TNF-a can induce cross tolerance to LPS, 79 thus TNF-a may be a autocrine factor involved in LPS tolerance. On the other hand, it has been found that LPS tolerance can be induced in TNF receptor I/II double knockout mice, which suggests that TNF-a is not involved in the mechanism of tolerance. 47 IL-10 is an anti-inflammatory cytokine, which suppresses expression of many cytokine genes such as TNFa, IL-1, and GM-CSF. Pretreatment of Mono-Mac-6 cells with LPS increases IL-10 mRNA expression upon LPS re-challenge. 114 IL-10 production is increased in response to LPS in monocytes from septic patients. 115 The up-regulation of IL-10 expression may induce down-regulation of pro-inflammatory cytokines. Studies with PBMC showed that IL-10 has similar effects in replacing LPS for induction of LPS tolerance. Neutralizing anti-IL-10 antibody prevented induction of LPS tolerance. 116 These data suggest that IL-10 is involved in mechanism of LPS tolerance. However, it has also been reported that in human PBMC and human dendritic cells, LPS pretreatment down-regulates IL-10 expression induced by LPS rechallenge. 117, 118 Berg et al. 116 presented data to suggest that IL-10 was not the effector of LPS tolerance since IL-10 deficient mice could be rendered LPS tolerance.
PGE 2 a metabolite of arachidonic acid is induced by LPS stimulation. It has been shown that PGE 2 suppress the cytokine response of both macrophages and lymphocytes. 119 Kupffer cells from LPS-tolerant rat produce more PGE 2 after rechallenge with LPS. 120 It was reported that in the peritoneal macrophage from BALBc mice, LPS pretreatment significantly augmented PGE 2 release by re-stimulation with LPS. 121 The augmentation of PGE 2 production in LPS tolerance was also found in human PBMC from healthy volunteers. 122 Augmentation of PGE 2 production in LPS tolerance suggests PGE 2 could be involved in the tolerance mechanism.
Zingarelli et al. 123 observed that in peritoneal macrophage from LPS tolerant rat, NO production was significantly increased by re-stimulation with LPS and that stimulation can be inhibited by selective NO synthase inhibitor L-NAME. L-NAME decreased the survival of rat rendered LPS tolerant upon LPS re-challenge. Conversely, molsidomine, a NO donor protected rats from LPS shock. Similarly, Bowling et al. 67 demonstrated that in LPS-tolerant RAW264.7 cells, NO production was increased by LPS re-challenge. These findings have been confirmed in mouse thioglycollate-elicited peritoneal macrophage and murine peritoneal exudate cells. 124, 125 However, some studies have demonstrated decrease NO production in LPS-tolerant cells. 126 These studies may reflect differences in the tolerance-inducing regimen. It has also been observed that inducible nitric oxide synthase (iNOS) mRNA expression was increased by LPS re-stimulation in Kupffer cells from PS-tolerant rat. 127 We recently demonstrated that iNOSdeficient mice can be rendered tolerant to LPS. These findings suggest nitric oxide is not required for the development of LPS tolerance.
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SUMMARY AND CONCLUSIONS
Endotoxin tolerance involves multiple changes in cell signal transduction pathways (Fig. 1) . Expression of LBP, CD14, MD-2, and TLR2 are unchanged or up-regulated, whereas TLR4 is transiently suppressed in murine macrophages but is unchanged in most other species. The findings that over expression of TLR4 does not alter the LPS-tolerant phenotype and cross tolerance to TLR2 agonists suggest that LPS tolerance cannot be solely attributed to changes in specific cell surface receptors. However, other LPS receptors exists and their potential change in expression during tolerance cannot be excluded. Adaptor proteins MyD88, TIRAP, and TRAF6 are not significantly changed during LPS tolerance. However, decreased TLR4-MyD88 association occurs. Decreased IRAK phosphorylation and its augmented degradation, decreased G i protein content and activity, decreased PKC activity, and reduction in MAP kinase activity in LPS tolerance. Not all signaling pathways are down-regulated and some proteins are up-regulated. The latter proteins may be counter regulatory and include IRAK-M, the PI3K pathway, and SOCS-1 expression. Increased or maintained expression IkB isoforms occurs as a consequence of reduced phosphorylation or degradation and/or augmented de novo synthesis. At the nuclear level, there is a decrease in AP-1 and NFkB transactivation but an increase in the p50 homodimer expression, which is inactive in initiating transcription. Increased nuclear expression of certain IkB isoforms (e.g. IkB-z) may also contribute to decreased NF-kB activation in LPS tolerance. Additionally, increased activation of PPAR-g in LPS tolerance may suppress proinflammatory gene expression.
These multiple changes in the cellular signaling pathway pose challenges to investigators in the field. There are apparent species and cell-phenotype differences and this is further complicated by in vitro autocrine mediators and in vivo non-myeloid paracrine factors that may modulate LPS tolerance. It remains to be determined if LPS tolerance involves a single critical signaling pathway for tolerance induction or sequential multiple changes in signaling events during induction and resolution. There are other important unresolved questions about LPS tolerance that go far beyond the present review. The phenomena of cross tolerance and priming response to other microbial stimuli and cross tolerance to ischemia/reperfusion injury and other non-microbial noxious stimuli are further perplexities that remain to be clarified. Perhaps the most complicated, but important, question is the clinical implication of LPS tolerance in critically ill patients. 4, 8 It is clear that LPS tolerance has evolved as a complex orchestrated counter-regulatory inflammatory adaptive response of fundamental importance in a variety of pathogenic conditions. Unraveling the molecular mechanisms of tolerance will have profound implications in our understanding of the biology of inflammation.
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